Status:

RECRUITING

Observational Study of Patients Treated With Nivolumab and Chemotherapy for Advanced or Metastatic Esophageal, Gastroesophageal or Gastric Cancer in France

Lead Sponsor:

Bristol-Myers Squibb

Conditions:

Gastric Adenocarcinoma

Gastro-esophageal Junction Adenocarcinoma

Eligibility:

All Genders

18+ years

Brief Summary

A study to estimate the overall survival in real-life conditions in France of adult participants treated with nivolumab in combination with chemotherapy as first-line treatment for gastric and gastroe...

Eligibility Criteria

Inclusion

  • Cohorts 1 \& 2
  • Adult participants (at least 18 years of age at time of treatment decision)
  • Participants treated with nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy (according to the French current marketing authorization) for the treatment of Gastric Adenocarcinoma, Gastro-Esophageal Junction (GEJ) adenocarcinoma, Esophageal Adenocarcinoma (EAC) or Esophageal Squamous Cell Carcinoma (ESCC) and prior to study participation.
  • Participants who provided oral informed consent to participate in the study
  • Cohort 1 only • Diagnosis of untreated HER2 negative advanced or metastatic gastric adenocarcinoma, GEJ adenocarcinoma or EAC whose tumor express PD-L1 with a CPS ≥5
  • Cohort 2 only
  • • Diagnosis of untreated unresectable advanced, recurrent or metastatic ESCC with tumor cell PD-L1 expression (TPS) ≥1%

Exclusion

  • Cohorts 1 \& 2
  • Participants with a primary diagnosis of a cancer other than advanced or metastatic gastric adenocarcinoma, GEJ adenocarcinoma, EAC or ESCC, within the past 5 years.
  • Participants currently enrolled in an interventional clinical trial for his/her advanced or metastatic gastric adenocarcinoma, GEJ adenocarcinoma, EAC or ESCC.
  • Pregnant women
  • Participants under guardianship

Key Trial Info

Start Date :

December 10 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 31 2028

Estimated Enrollment :

500 Patients enrolled

Trial Details

Trial ID

NCT06504615

Start Date

December 10 2024

End Date

August 31 2028

Last Update

December 13 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

KAPPA SANTE Institution

Paris, France, 75002

2

Kappa Santé

Paris, France